[go: up one dir, main page]

WO2021040086A1 - Nouvelles bactéries d'acide lactique, et composition et aliment fonctionnel pour la santé, chacun d'eux les comprenant - Google Patents

Nouvelles bactéries d'acide lactique, et composition et aliment fonctionnel pour la santé, chacun d'eux les comprenant Download PDF

Info

Publication number
WO2021040086A1
WO2021040086A1 PCT/KR2019/011010 KR2019011010W WO2021040086A1 WO 2021040086 A1 WO2021040086 A1 WO 2021040086A1 KR 2019011010 W KR2019011010 W KR 2019011010W WO 2021040086 A1 WO2021040086 A1 WO 2021040086A1
Authority
WO
WIPO (PCT)
Prior art keywords
strain
composition
extract
lactic acid
culture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2019/011010
Other languages
English (en)
Korean (ko)
Inventor
서정민
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neoregen Biotech
Original Assignee
Neoregen Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neoregen Biotech filed Critical Neoregen Biotech
Priority to PCT/KR2019/011010 priority Critical patent/WO2021040086A1/fr
Publication of WO2021040086A1 publication Critical patent/WO2021040086A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/10—Animals; Substances produced thereby or obtained therefrom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/25—Lactobacillus plantarum

Definitions

  • the present invention relates to a novel lactic acid bacteria, a composition comprising the same, and a health functional food.
  • Lactobacillus is one of the most beneficial microorganisms available to humans, and has a long history and has a direct or indirect relationship with human life. Lactobacillus is widely distributed in nature, such as the oral cavity, digestive tract, and soil of mammals as well as food, and is a beneficial strain for human life that plays an important role related to food preservation and organoleptic properties.
  • lactic acid bacteria is conceptual and not a taxonomic scientific name for bacteria. Bacteria that produce about 50% or more of lactic acid as metabolites with respect to sugar consumed are called lactic acid bacteria. Unlike E. coli, it does not produce decay products. Therefore, bacteria that produce a large amount of lactic acid from sugars, do not produce substances harmful to the human body in the intestines of humans and animals, and prevent decay, are conceptually referred to as lactic acid bacteria. Lactobacillus in a common concept is Gram-positive cocci or bacillus, catalase negative (anaerobic fermentation), does not form spores, and generally has no motility.
  • Lactic acid bacteria produce various antibacterial substances and organic acids such as lactic acid and acetic acid with antibacterial activity. Lactobacillus produces hydrogen peroxide in the presence of oxygen and does not have catalase activity, so it secretes hydrogen peroxide into the medium and accumulates it to a concentration that has microbial inhibition.
  • diacetyl one of the non-proteinaceous antimicrobial substances produced by lactic acid bacteria, is one of the representative flavor components of lactic acid bacteria fermented products, and has a strong inhibitory effect against pathogenic microorganisms by interacting with pH.
  • bacteriocin is a protein or protein complex material having a relatively small molecular weight and inhibits other microorganisms by disrupting the proton motive force of the bacterial cell membrane. Most of them are stable to heat and are stable even at low pH, but most of them are inactivated by proteolytic enzyme treatment.
  • Nisin a representative lactic acid bacteria-derived bacteriocin substance, is produced from Lactococcus lactis and has been commercially accepted for a long time because of its broad antimicrobial activity. Lactococcin), Pediocin, and the like are known.
  • An object of the present invention is to provide a novel lactic acid bacteria.
  • An object of the present invention is to provide a composition and health functional food utilizing various activities and functions of novel lactic acid bacteria.
  • the present invention provides Lactobacillus plantarum L-14 (Lactobacillus plantarum L-14) KCTC13497BP.
  • the present invention provides a composition comprising Lactobacillus plantarum L-14 (Lactobacillus plantarum L-14) KCTC13497BP, a culture solution or an extract thereof.
  • the present invention provides a health functional food comprising Lactobacillus plantarum L-14 (Lactobacillus plantarum L-14) KCTC13497BP, a culture solution or an extract thereof.
  • Lactobacillus plantarum L-14 (Lactobacillus plantarum L-14) KCTC13497BP strain of the present invention exhibits various activities such as antibacterial, anti-inflammatory, anti-cancer, adipocyte differentiation inhibition, and anti-obesity.
  • KCTC13497BP strain of the present invention exhibits various activities such as antibacterial, anti-inflammatory, anti-cancer, adipocyte differentiation inhibition, and anti-obesity.
  • it can be preferably used as a pharmaceutical composition, health functional food, cosmetic composition, and the like.
  • Figure 1 is a micrograph of Lactobacillus plantarum L-14 (Lactobacillus plantarum L-14) KCTC13497BP, and the turbidity (O.D.) of the culture, and the number of viable cells (colony forming unit; CFU) was measured.
  • Figure 2 shows the metabolism of Lactobacillus plantarum L-14 (Lactobacillus plantarum L-14) KCTC13497BP.
  • Figure 9 shows the anti-inflammatory effect of Lactobacillus plantarum L-14 (Lactobacillus plantarum L-14) KCTC13497BP.
  • Lactobacillus plantarum L-14 Lactobacillus plantarum L-14
  • KCTC13497BP Lactobacillus plantarum L-14
  • Figure 22 shows the skin irritation relief effect of Lactobacillus plantarum L-14 (Lactobacillus plantarum L-14) KCTC13497BP.
  • the present invention relates to a novel lactic acid bacteria Lactobacillus plantarum L-14 (Lactobacillus plantarum L-14) KCTC13497BP.
  • the strain was deposited with the Korea Research Institute of Bioscience and Biotechnology Biological Resource Center on March 15, 2018, and the accession number is KCTC13497BP.
  • the strain may have glycogen metabolism, L-arabinose or ⁇ -methyl-D-mannoside metabolism, and may metabolize all of the sugars.
  • the strain is excellent in viability, and for example, the number of viable cells may not decrease until 48 hours when cultured in a culture medium.
  • the strain has a remarkably fast growth rate with reproducible ability.
  • the generation time (doubling time) may be within 20 minutes, specifically within 15 minutes. This is a growth rate similar to that of food poisoning bacteria, and is significantly faster than other conventional lactic acid bacteria (Lactobacillus genus).
  • lactobacillus genus lactic acid bacteria
  • the strain or its culture has several excellent activities. For example, it is an effect of inhibiting the growth of harmful microorganisms, an anti-inflammatory effect, an anti-cancer effect, and an effect of inhibiting differentiation of adipocytes.
  • the strain, its culture or its extract may be used as an antibacterial composition, a pharmaceutical composition, an anti-inflammatory composition, a health functional food, and the like.
  • the culture may include the strain, or the strain may be an isolated culture.
  • the present invention relates to a composition
  • a composition comprising Lactobacillus plantarum L-14 (Lactobacillus plantarum L-14) KCTC13497BP, a culture thereof or an extract thereof.
  • the culture of the Lactobacillus plantarum L-14 KCTC13497BP strain includes a medium containing the strain (solid, liquid, etc.), and after culturing the strain, a medium from which the strain is isolated (solid, liquid, etc.). I can.
  • the extract of the strain may be, for example, a lysate of the strain, and specifically, may be a powder obtained by lyophilizing the lysate of the strain or a solution or dispersion thereof.
  • the composition may be an antibacterial composition.
  • Lactobacillus plantarum L-14 (Lactobacillus plantarum L-14) KCTC13497BP, its culture or its extract may exhibit antimicrobial activity against various harmful bacteria.
  • Examples of harmful bacteria may be microorganisms belonging to the genus Staphylococcus, the genus Streptococcus, the genus Enterococcus, the genus Pseudomonas, the genus Escherichia, and the like, and specific examples are Staphylococcus aureus, S. aureus. ), Streptococcus mutans (S.mutans), Enterococcus faecalis (E.faecalis), Pseudomonas aeruginosa; P.aeruginosa, Escherichia coli, Esichia coli (Esichia coli, E. .coli) or the like, but is not limited thereto.
  • the antimicrobial composition of the present invention may exhibit excellent antimicrobial activity against harmful bacteria as described above, without having a significant effect on beneficial bacteria such as lactic acid bacteria or other bacteria.
  • composition may be a pharmaceutical composition for preventing or treating diseases caused by the bacteria.
  • Harmful bacteria such as the genus Staphylococcus, Streptococcus, Enterococcus, Pseudomonas, and Escherichia are known to cause various diseases, and for specific examples, Staphylococcus aureus is food poisoning and sepsis. Etc., and Streptococcus mutans, Enterococcus faecalis, etc. induce tooth decay, oral diseases, etc., and Pseudomonas aruginosa is known to cause endocarditis, pneumonia, meningitis, etc. It can be utilized as a pharmaceutical composition for prophylaxis or treatment. In addition to those exemplified above, it may exhibit a preventive or therapeutic effect on all diseases known to be caused by the above bacteria.
  • composition may be an anti-inflammatory composition.
  • Lactobacillus plantarum L-14 (Lactobacillus plantarum L-14) KCTC13497BP, its culture or its extract has an effect of inhibiting the secretion of inflammatory cytokines of macrophages, can exhibit excellent anti-inflammatory effect.
  • composition may be a pharmaceutical composition for preventing or treating inflammatory diseases.
  • the inflammatory diseases include, for example, atopic dermatitis, edema, dermatitis, allergy, asthma, conjunctivitis, periodontitis, rhinitis, otitis media, sore throat, tonsillitis, pneumonia, gastric ulcer, gastritis, Crohn's disease, colitis, hemorrhoids, gout, hepatic spondylitis, Rheumatoid heat lupus, fibromyalgia, psoriatic arthritis, osteoarthritis, rheumatoid arthritis, peri-shoulder joint infection, tendinitis, tendonitis, myositis, hepatitis, cystitis, nephritis, sjogren's syndrome, multiple sclerosis, etc. It is not.
  • composition may be a pharmaceutical composition for preventing or treating cancer.
  • Lactobacillus plantarum L-14 (Lactobacillus plantarum L-14) KCTC13497BP, its culture or its extract has excellent cancer cell lowering effect, thereby reducing tumor size.
  • the pharmaceutical composition of the present invention can be applied without limitation to cancer known in the art, for example, brain tumor, gastric cancer, lung cancer, breast cancer, ovarian cancer, liver cancer, bronchial cancer, nasopharyngeal cancer, laryngeal cancer, esophageal cancer, pancreatic cancer, bladder cancer, prostate cancer. Cancer, colon cancer, head and neck cancer, skin cancer, melanoma, colon cancer, and cervical cancer, and the like, but are not limited thereto. For a specific example, it may be a melanoma.
  • composition may be a composition for inhibiting adipocyte differentiation or a composition for anti-obesity.
  • Lactobacillus plantarum L-14 (Lactobacillus plantarum L-14) KCTC13497BP, its culture or its extract can inhibit the differentiation of adipocytes into adipocytes and stem cells into adipocytes.
  • the stem cells may be, for example, embryonic stem cells, adult stem cells, or induced pluripotent stem cells, and adult stem cells may be mesenchymal stem cells, but are not limited thereto.
  • composition of the present invention may be administered orally, parenteral, rectal, topical, transdermal, intravenous, intramuscular, intraperitoneal, subcutaneous, and the like.
  • Formulations for oral administration may be tablets, pills, soft and hard capsules, granules, powders, fine granules, liquids, emulsions, or pellets, but are not limited thereto.
  • Formulations for parenteral administration may be solutions, suspensions, emulsions, gels, injections, drops, suppositories, patches, ointments, or sprays, but are not limited thereto.
  • the formulation can be easily prepared according to a conventional method in the art, and a surfactant, an excipient, a wetting agent, an emulsification accelerator, a suspending agent, a salt or buffer for controlling the osmotic pressure, a colorant, a spice, a stabilizer, a preservative, a preservative or Other commonly used adjuvants may be additionally included.
  • the applied amount or dosage of the composition of the present invention will vary depending on the age, sex, weight, pathological condition and severity of the subject to be administered, the route of administration, or the judgment of the prescriber. Determination of the applied amount based on these factors is within the level of those skilled in the art, and the daily dose of the active ingredient is, for example, 0.0001 ⁇ g/kg/day to 5000 mg/kg/day, more specifically 0.00001 mg/kg/day to 15 mg. It may be /kg/day, but is not limited thereto.
  • the present invention relates to a health functional food comprising Lactobacillus plantarum L-14 (Lactobacillus plantarum L-14) KCTC13497BP, its culture or its extract.
  • the health functional food of the present invention may have health functions (prevention or improvement) such as antibacterial, anti-inflammatory, anti-cancer, adipocyte differentiation inhibition, or anti-obesity.
  • the formulation of the health functional food of the present invention is not particularly limited, but may be formulated as, for example, a tablet, granule, pill, powder, capsule, liquid such as a drink, caramel, gel, bar, tea bag, or the like.
  • the food composition or health food composition of each formulation can be appropriately selected and blended by a person skilled in the art according to the formulation or purpose of use, depending on the formulation or purpose of use. Can happen.
  • the health functional food of the present invention may be administered by various methods such as simple intake, drinking, injection administration, spray administration, or squeeze administration.
  • the determination of the dosage of the active ingredient is within the level of those skilled in the art, and the daily dosage thereof may be, for example, 0.00001 mg/kg/day to 15 mg/kg/day,
  • the present invention is not limited thereto, and may vary depending on various factors such as age, health status, and complications of the target to be administered.
  • the health functional food of the present invention may be, for example, various foods such as chewing gum, caramel products, candies, frozen desserts, sweets, beverage products such as soft drinks, mineral water, alcoholic beverages, and health functional foods including vitamins or minerals. have.
  • the health functional food of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavors and natural flavoring agents, coloring agents and enhancers (cheese, chocolate, etc.), pectic acid and salts thereof, alginic acid and salts thereof. , Organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonates used in carbonated beverages, and the like.
  • the health functional food of the present invention may include flesh for the manufacture of natural fruit juice and fruit juice beverages and vegetable beverages. These components may be used independently or in combination. The proportion of these additives is not so important, but is generally included in the range of 0 to about 50 parts by weight per 100 parts by weight of the composition according to an aspect of the present invention.
  • the present invention relates to a cosmetic composition
  • a cosmetic composition comprising the Lactobacillus plantarum L-14 (Lactobacillus plantarum L-14) KCTC13497BP, the culture or an extract thereof.
  • the cosmetic composition of the present invention may have the anti-inflammatory activity described above.
  • the cosmetic composition of the present invention may be for relieving skin irritation.
  • the cosmetic composition of the present invention may include ingredients commonly used in cosmetic compositions in addition to the above as an active ingredient, for example, conventional auxiliary agents such as antioxidants, stabilizers, solubilizers, vitamins, pigments and fragrances, and carriers. can do.
  • conventional auxiliary agents such as antioxidants, stabilizers, solubilizers, vitamins, pigments and fragrances, and carriers. can do.
  • the cosmetic composition of the present invention may be prepared in any formulation conventionally prepared in the art, for example, a solution, a suspension, an emulsion, a paste, a gel, a cream, a lotion, a powder, a soap, a surfactant containing cleansing, It can be formulated as an oil, powder foundation, emulsion foundation, wax foundation and spray. However, it is not necessarily limited thereto. In more detail, it may be prepared in the form of a flexible lotion, astringent lotion, a nutrition lotion, a nutrition cream, a massage cream, an essence, an eye cream, a cleansing cream, a cleansing foam, a cleansing water, a pack, a spray, or a powder.
  • the formulation of the cosmetic composition of the present invention is a paste, cream, or gel
  • a carrier component animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide, etc. Can be used.
  • lactose When the formulation of the cosmetic composition of the present invention is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component.
  • Propellants such as carbon, propane/butane or dimethyl ether.
  • a solvent, a solubilizing agent or an emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene Glycol, 1,3-butylglycol oil, glycerol aliphatic ester, polyethylene glycol or fatty acid ester of sorbitan.
  • the formulation of the cosmetic composition of the present invention is a suspension
  • a liquid diluent such as water, ethanol or propylene glycol, an ethoxylated isostearyl alcohol, a suspending agent such as polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester , Microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tracant, and the like may be used.
  • the formulation of the cosmetic composition of the present invention is a surfactant containing cleansing, as carrier components, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, Fatty acid amide ether sulfates, alkylamidobetaines, fatty alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters may be used.
  • Colonies were randomly collected, re-inoculated in MRS medium, and cultured at 37°C for 18 hours. 98 strains were obtained through the screening process, which were added to glycerol at a final concentration of 15% and frozen at -80°C.
  • PCR sequencing was performed by Cosmo Gentech (Daejeon, Korea).
  • L14 To calculate the doubling time of L14, it was inoculated into MRS medium and cultured at 37°C. The absorbance was measured at 600 nm using a microplate reader (Molecular Devices, LLC, CA, USA) and a colony forming unit (CFU/mL), spreading L14 on the MRS agar plate at regular intervals, and counting the number of colonies.
  • a microplate reader Molecular Devices, LLC, CA, USA
  • CFU/mL colony forming unit
  • L14 cells were straight, rounded at the end, 0.6-0.9 ⁇ m in width, and 1.2-2.4 ⁇ m in length, in the form of a rod (Fig. 1).
  • the turbidity and viable cell count change graph showed consistent improvement, and it was confirmed that the viable cell count did not decrease until about 48 hours.
  • L14 The metabolic properties of L14 were confirmed using an API identification kit. When compared with the experimental results of the API 50 CHL kit used for the identification of lactic acid bacteria and the metabolic ability table of standard L. plantarum written in the kit manual, it was confirmed that L14 has the metabolic ability closest to L. plantarum (Fig. 2). Reference).
  • the principle of the API kit is to grow bacteria in a kit strip containing 50 kinds of sugar to see if it can metabolize sugar. If it can metabolize a specific sugar, the color changes from purple to yellow due to pH change.
  • L14 has Glycogen metabolism ability differently from Company A's L. plantarum ML PRIMETM (LALLEMAND, South Australia, Australia, hereinafter LS), and Company B's L. plantarum lactofy kimchi lactobacillus (Probiotic Co., Ltd., Jeollabuk-do , Jeonju, LP), it can be seen that it has the ability to metabolize L-arabinose.
  • ML contained 4.5% (w/v) MRS, 1.25% (w/v) LB and 1.5% (w/v) agar.
  • MT contained 4.5% (w/v) of MRS, 1.5% (w/v) of TSB and 1.5% (w/v) of agar.
  • E. coli was pre-cultured in LB medium, and the other four pathogens (MRSA, P. aeruginosa, S. mutans, and E. faecalis) were cultured in TSB medium. The surface of the culture dish containing the MRS medium was wiped with LB or TSB as an indicator strain of the pathogen.
  • a commercially available paper disc (7 mm in diameter, ADVANTEC, Taipei, Taiwan) was placed in 20 ⁇ L of 7 log CFU/ ⁇ L of L14, 20 ⁇ L of 7 log CFU/ ⁇ L of commercial L. reuteri or 20 ⁇ L of ampicillin (1.0 mg/ ⁇ L). mL) was added. Paper discs were gently placed on the surface of each media and incubated at 37° C. for 1-2 days before assessing the formation of a microbial growth inhibition zone around the disc.
  • L14 exhibits antimicrobial properties similar to those of commercially available antimicrobial L. reuteri
  • disc diffusion analysis using 3 groups (negative control, L14 and L. reuteri treatment groups) was performed.
  • L14 significantly inhibited the growth of E. coli (p ⁇ 0.01), MRSA (p ⁇ 0.05), and E. faecalis (p ⁇ 0.01) compared to L. reuteri, which is known to have an antibacterial effect (Fig. 3).
  • Escherichia coli Escherichia coli
  • Staphylococcus aureus S. aureus
  • Pseudomonas aeruginosa P. aeruginosa
  • Live L14 bacteria have the ability to inhibit the growth of Escherichia coli (E. coli), Staphylococcus aureus (S. aureus), and Pseudomonas aeruginosa (P. aeruginosa), which can cause food poisoning and sepsis.
  • E. coli Escherichia coli
  • S. aureus Staphylococcus aureus
  • P. aeruginosa Pseudomonas aeruginosa
  • L14 was inoculated in 5 mL of MRS liquid medium
  • E. coli was inoculated in 5 mL of LB liquid medium
  • S. aureus and P. aeruginosa were inoculated in 5 mL of TSB liquid medium, respectively, and cultured at 37°C for 18 hours.
  • To 100 mL of distilled water 3.66 mg of commercially available MRS medium powder, 1 mg of LB medium powder, 1 mg of TSB medium powder, and 1.5 mg of agar were added and sterilized with an autoclave. Thereafter, when the medium was sufficiently cooled, 1 mL of E. coli, S. aureus, and P.
  • aeruginosa cultured in the above LB and TSB liquid medium was added each, and after sufficiently mixing, poured into a petri dish to make a solid medium. . After centrifuging the cultured L14 bacteria at 12,000 g for 3 min, only about 500 ⁇ L of the medium was left, and the supernatant was removed, and then resuspended with the remaining liquid medium (1/10 concentration). 20 ⁇ L of PBS (Negative control; NC), antibiotic ampicillin (1 mg/mL), and concentrated L14 live bacteria were inoculated on sterilized disk paper, placed on a solid medium, and cultured at 37°C for 18 hours.
  • NC Native control
  • antibiotic ampicillin (1 mg/mL
  • concentrated L14 live bacteria were inoculated on sterilized disk paper, placed on a solid medium, and cultured at 37°C for 18 hours.
  • L14 live bacteria inhibit the growth of surrounding E. coli and S. aureus bacteria.
  • it has the effect of inhibiting harmful bacteria such as ampicillin at a concentration 10 times higher than the concentration used in the existing laboratory (0.1 mg/mL).
  • L14 has an antibacterial effect against Pseudomonas aeruginosa, which has no effect on the antibiotic ampicillin.
  • Streptococcus mutans S.mutans
  • Enterococcus faecalis E.faecalis
  • L14 live bacteria were confirmed to have the ability to inhibit growth against the harmful microorganisms Streptococcus mutans (S. mutans) and Enterococcus faecalis (E. faecalis), which are known to cause tooth decay and oral disease.
  • L14 bacteria were inoculated into 5 mL of MRS liquid medium, and S.mutans and E.faecalis were inoculated into 5 mL of TSB liquid medium, respectively, and cultured at 37°C for 18 hours.
  • MRS liquid medium To 100 mL of distilled water, 3.66 mg of commercially available MRS medium powder, 1 mg of TSB medium powder, and 1.5 mg of agar were added and sterilized with an autoclave.
  • 1 mL each of S. mutans and E. faecalis cultivated in the above TSB liquid medium was added, thoroughly mixed, and poured into a petri dish to make a solid medium.
  • FIGS. 4 and 5 The results of FIGS. 4 and 5 are shown in a graph in FIG. 6.
  • Staphylococcus aureus S.aureus
  • Pseudomonas aeruginosa P.aeruginosa
  • the culture solution was separated, and 20 ⁇ L of distilled water and L14 culture solution were inoculated on sterilized disk paper and placed on a solid medium in which S.aureus and P.aeruginosa were already inoculated to grow S.aureus and P.aeruginosa. The inhibitory ability was confirmed.
  • L14 bacteria were inoculated into 5 mL of MRS liquid medium and S.aureus and P.aeruginosa were inoculated into 5 mL of TSB liquid medium, respectively, and cultured at 37°C for 18 hours.
  • MRS liquid medium To 100 mL of distilled water, 3.66 mg of commercially available MRS medium powder, 1 mg of TSB medium powder, and 1.5 mg of agar were added and sterilized with an autoclave.
  • 1 mL each of S.aureus and P.aeruginosa cultured in the above TSB liquid medium was added, mixed sufficiently, and poured into a petri dish to make a solid medium.
  • the L14 culture medium inhibits the growth of S. aureus and P. aeruginosa bacteria in comparison with the disk paper inoculated with distilled water (control).
  • L14 and harmful bacteria E. coli and S. aureus
  • L14 when L14 is inoculated together, it has the effect of inhibiting the growth of E. coli and S. aureus irrespective of CFU.
  • L14 is inoculated with 1/100 of E. coli and 1/10 of S. aureus. It can be seen that it also inhibits growth when done.
  • L14 directly acts on mouse macrophages known as immune cells (ATCC RAW 264.7) to inhibit the secretion of inflammation-inducing cytokines.
  • RAW264.7 was inoculated into a 12 well plate at 1.0 ⁇ 10 6 cells/well and stabilized for one day. The next day, L14, previously cultured, was inoculated at 1.0 ⁇ 10 6 CFU/mL and incubated for 6 hours. While replacing with a new medium, 10-100 ug/mL of endotoxin lipopolysaccharide (LPS), which is an inflammation inducing substance, was inoculated. After incubation for 6 hours, the culture solution was separated, and the inflammatory cytokines contained in the separated culture solution were quantified through enzyme immunoassay (ELISA).
  • LPS endotoxin lipopolysaccharide
  • L14 lactic acid bacteria extract was prepared as follows. First, L14 lactic acid bacteria were inoculated into 10 mL of sterilized MRS liquid medium and cultured at 35° C. for 18 hours (pre-culture). The cultured L14 lactic acid bacteria were inoculated into 1 L of sterilized MRS liquid medium and cultured at 35° C. for 18 hours (main culture). The main cultured L14 bacteria were centrifuged at 4°C, 12,000g, 15 min, and then the supernatant was removed and only L14 bacteria were obtained. After resuspending with PBS, centrifugation at 4° C., 12,000 g, 15 min, and then removing the supernatant was repeated twice.
  • L14 lactic acid bacteria extract against melanoma cell lines in vitro was confirmed as follows.
  • Human dermal fibroblast (HDF) and human melanoma cell lines A375P and A375SM were inoculated at 10,000 cells/well in 12 well plates and 1,000 cells/well in 96 well plates and cultured for 24 hours.
  • the L14 lactic acid bacteria extract was treated with different concentrations.
  • the anticancer effect of the L14 lactobacillus extract was observed through a microscope in a 12 well plate, and confirmed by WST-1 viability assay in a 96 well plate.
  • the anticancer activity of the human melanoma cell line A375SM of L14 lactic acid bacteria extract was confirmed in vivo.
  • Tumors were artificially generated by subcutaneous inoculation of the A375SM cell line in immune-deficient nude mice, and the groups were randomly divided and intraperitoneally injected with PBS and L14 lactobacillus extract at 2-day intervals for 22 days. Referring to Figure 12, it can be seen that the tumor size of the group nude mice treated with L14 lactic acid bacteria extract is smaller than that of the control group.
  • L14 lactobacillus extract was confirmed to inhibit the differentiation of mouse adipocyte progenitor cell lines (3T3-L1) and human mesenchymal stem cells (hMSCs) into adipocytes.
  • 3T3-L1 was inoculated into 24 well plates at 100,000 cells/well and cultured for several days.
  • the medium was changed with an adipocyte differentiation induction medium (MDI medium) and L14 lactic acid bacterium extract was treated with each concentration at the same time (Day 0).
  • the medium was changed with the adipocyte differentiation induction medium, and the L14 lactic acid bacteria extract was treated again.
  • the medium was changed to adipocyte differentiation maintenance medium, and the medium was changed every 2 days until Day 12.
  • TAG Triacylglycerol
  • hMSCs were inoculated into 24 well plates at 100,000 cells/well and cultured for several days.
  • the medium was changed with an adipocyte differentiation induction medium (MDI medium) and L14 lactic acid bacterium extract was treated with each concentration at the same time (Day 0).
  • the medium was changed with the adipocyte differentiation induction medium, and the L14 lactic acid bacteria extract was treated again.
  • the medium was changed to adipocyte differentiation maintenance medium, and the medium was changed every 2 days until Day 7. The effect of inhibiting adipocyte differentiation was confirmed through the oil red o staining method using the cells of Day 7 that were differentiated into adipocytes.
  • AICAR AMPK activator
  • Compound C AMPK inhibitor, Dorsomorphin
  • the skin barrier was artificially damaged by designating the sample use and unused area on the test site (left forearm) and applying 1% SLS (Sodium Lauryl Sulfate) for 24 hours.
  • SLS Sodium Lauryl Sulfate
  • the amount of transepidermal water evaporation on the used and unused samples was measured with a Vapometer (Delfin, Finland) according to the measurement schedule. Each measurement was performed once, and the unit was expressed in g/m2/h. In addition, it was taken with Antera 3D CS (Miravex, Ireland) for photo data. As the measured value decreases, it means improvement.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Agronomy & Crop Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)

Abstract

La présente invention concerne une souche de Lactobacillus plantarum L-14 KCTC13497BP, et une composition et un aliment fonctionnel pour la santé, chacun d'eux les comprenant, la souche présentant diverses activités telles qu'une activité antibactérienne, une activité anticancéreuse, une inhibition de la différenciation en adipocytes, une activité anti-obésité, etc. ; la souche peut être de préférence utilisée dans une composition médicinale, un aliment fonctionnel pour la santé, et cetera.
PCT/KR2019/011010 2019-08-28 2019-08-28 Nouvelles bactéries d'acide lactique, et composition et aliment fonctionnel pour la santé, chacun d'eux les comprenant Ceased WO2021040086A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/KR2019/011010 WO2021040086A1 (fr) 2019-08-28 2019-08-28 Nouvelles bactéries d'acide lactique, et composition et aliment fonctionnel pour la santé, chacun d'eux les comprenant

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2019/011010 WO2021040086A1 (fr) 2019-08-28 2019-08-28 Nouvelles bactéries d'acide lactique, et composition et aliment fonctionnel pour la santé, chacun d'eux les comprenant

Publications (1)

Publication Number Publication Date
WO2021040086A1 true WO2021040086A1 (fr) 2021-03-04

Family

ID=74683846

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2019/011010 Ceased WO2021040086A1 (fr) 2019-08-28 2019-08-28 Nouvelles bactéries d'acide lactique, et composition et aliment fonctionnel pour la santé, chacun d'eux les comprenant

Country Status (1)

Country Link
WO (1) WO2021040086A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116121110A (zh) * 2022-10-28 2023-05-16 益加生物科技成都有限公司 一种抑菌和抗炎作用较强的乳酸乳球菌yj0801及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009102143A2 (fr) * 2008-02-11 2009-08-20 Bioleaders Corporation Lactobacillus plantarum bls41 issu du kimchi et son utilisation
KR20120034482A (ko) * 2010-10-01 2012-04-12 주식회사한국야쿠르트 지방세포 분화 유도에 관여하는 유전자의 발현을 억제함으로써 지방세포 분화 억제 효능을 갖는 락토바실러스 플란타룸 케이와이1032 및 이를 유효성분으로 함유하는 제품
KR20170050527A (ko) * 2015-10-30 2017-05-11 대상 주식회사 신선유지를 위한 항균 및 항진균 활성을 갖는 식물성 유산균 락토바실러스 플란타륨 dsr kf15 및 이의 용도
KR20170093586A (ko) * 2016-02-05 2017-08-16 명지대학교 산학협력단 프로바이오틱 활성을 갖는 신규 락토바실러스 플란타럼 및 이의 용도
KR102021558B1 (ko) * 2018-03-16 2019-09-16 (주)네오리젠바이오텍 신규한 유산균, 이를 포함하는 조성물 및 건강기능식품

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009102143A2 (fr) * 2008-02-11 2009-08-20 Bioleaders Corporation Lactobacillus plantarum bls41 issu du kimchi et son utilisation
KR20120034482A (ko) * 2010-10-01 2012-04-12 주식회사한국야쿠르트 지방세포 분화 유도에 관여하는 유전자의 발현을 억제함으로써 지방세포 분화 억제 효능을 갖는 락토바실러스 플란타룸 케이와이1032 및 이를 유효성분으로 함유하는 제품
KR20170050527A (ko) * 2015-10-30 2017-05-11 대상 주식회사 신선유지를 위한 항균 및 항진균 활성을 갖는 식물성 유산균 락토바실러스 플란타륨 dsr kf15 및 이의 용도
KR20170093586A (ko) * 2016-02-05 2017-08-16 명지대학교 산학협력단 프로바이오틱 활성을 갖는 신규 락토바실러스 플란타럼 및 이의 용도
KR102021558B1 (ko) * 2018-03-16 2019-09-16 (주)네오리젠바이오텍 신규한 유산균, 이를 포함하는 조성물 및 건강기능식품

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116121110A (zh) * 2022-10-28 2023-05-16 益加生物科技成都有限公司 一种抑菌和抗炎作用较强的乳酸乳球菌yj0801及其应用

Similar Documents

Publication Publication Date Title
WO2019151843A1 (fr) Souche de lactobacillus plantarum kbl396 et son utilisation
CA2998877C (fr) Souche de lactobacilles johnsonii et son utilisation pour la prevention et le traitement de maladies degeneratives du cerveau ou de troubles de la fonction cognitive
WO2011010770A1 (fr) Nouvelle souche de lactobacillus plantarum et composition la contenant
WO2014193014A1 (fr) Bactéries lactiques de taille nanométrique issues du kimchi
WO2010064777A1 (fr) Nouveau lactobacillus plantarum et composition le contenant
WO2011007922A1 (fr) Nouveau lactobacillus plantarum et composition en contenant
WO2020075949A1 (fr) Nouvelle souche de lactobacillus plantarum atg-k2, atg-k6 ou atg-k8 et composition de prévention ou de traitement de la vaginite comprenant celle-ci
WO2018174369A1 (fr) Produit de colostrum fermenté par des bactéries lactiques et composition cosmétique l'utilisant
WO2018164468A1 (fr) Souche de bacillus amyloliquefaciens gf423, et composition ayant des activités anti-oxydantes et anti-inflammatoires ou de prévention ou de traitement de l'hyperlipidémie, y compris un polypeptide produit par celle-ci
WO2020040407A1 (fr) Nouvelle souche de cutibacterium avidum, et composition pour prévenir ou traiter la dermatite atopique, comprenant une souche ou un produit cultivé associé
WO2017047962A1 (fr) Nouveau lactobacillus et composition pour prévenir, atténuer ou traiter des maladies cérébrales dégénératives ou des troubles de la fonction cognitive
WO2019199048A1 (fr) Souche gen3013 de lactococcus lactis et composition de prévention ou de traitement du cancer la comprenant
WO2019088379A1 (fr) Nouvelles bactéries lactiques et leur utilisation
WO2020040408A1 (fr) Nouvelle souche de cutibacterium granulosum, et composition comprenant une telle souche ou une culture de ladite souche pour prévenir ou traiter l'acné
WO2019226002A1 (fr) Souche de lactobacillus crispatus kbl693 et utilisation associée
WO2023055188A1 (fr) Nouveaux probiotiques et utilisation associée
KR100996056B1 (ko) 대장염 발생 예방 효능을 가진 락토바실러스 브레비스에이치와이7401 및 이를 유효성분으로 함유하는 제품
WO2024048934A1 (fr) Nouvelle bactérie lactique lactiplantibacillus plantarum sko-001 pour réduire la graisse corporelle, et ses utilisations
WO2022203302A1 (fr) Souche de lactobacillus fermentum ayant pour effet de prévenir ou d'améliorer une maladie buccale et son utilisation
KR101979761B1 (ko) 락토바실러스 플란타룸 hy7715를 유효성분으로 함유하는 미세먼지에 의한 피부의 손상 방지 및 개선을 위한 조성물
WO2023038419A1 (fr) Souche de protection de la santé intestinale lactobacillus paracasei eps da-bacs possédant des effets favorisant la croissance de lactobacillus bifidus et inhibant les bactéries intestinales nuisibles clostridium difficile, et son polysaccharide
WO2025071063A1 (fr) Composition cosmétique comprenant un produit de fermentation double d'extrait de kunzea ericoides
WO2022086041A1 (fr) Nouvelle souche de lactobacillus sp. et son utilisation
WO2012169842A2 (fr) Lactobacillus plantarum inédit isolé à partir de feuilles de camellia sinensis
WO2010064778A1 (fr) Nouveau lactobacillus plantarum et composition le contenant

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19943558

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19943558

Country of ref document: EP

Kind code of ref document: A1